drugset / Trial / NCT04331080

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

NCT04331080 ↗

Phase 2/3 Completed 184 enrolled Xequel Bio, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate effectiveness of Granexin® gel in reducing scar formation in surgical incisional wounds.

Timeline

Start
2020-07-01
Primary completion
2022-05-26
Completion
2022-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject ACT-1 PEPTIDE Peptide 100 unknown Topical
Subject ACT-1 PEPTIDE Peptide 200 unknown Topical

Indications